关注并星标CPHI制药在线百济神州三季报交上了一份高分的答卷,2025年第三季度,百济神州实现营收14.12亿美元,同比去年第三季度增长41%;2025年前三季度,百济神州实现营收38.45亿美元,同比去年前三季度增长43%。百济神州的增长引擎还没有放缓,以泽布替尼为代表的产品矩阵仍在保持着强劲的动力。此外,百济神州的后续管线持续发力也在跟进,我们可以看到它在血液瘤上的三位一体布局,可以看到它在...
Source Link关注并星标CPHI制药在线百济神州三季报交上了一份高分的答卷,2025年第三季度,百济神州实现营收14.12亿美元,同比去年第三季度增长41%;2025年前三季度,百济神州实现营收38.45亿美元,同比去年前三季度增长43%。百济神州的增长引擎还没有放缓,以泽布替尼为代表的产品矩阵仍在保持着强劲的动力。此外,百济神州的后续管线持续发力也在跟进,我们可以看到它在血液瘤上的三位一体布局,可以看到它在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.